Gluten Free Therapeutics Launches Celi•Vites Bone Health

Share Article

Third supplement complements innovative line of vitamins for celiacs

Gluten Free Therapeutics, the makers of Celi•Vites (, a line of scientifically formulated supplements designed specifically for those suffering from the debilitating effects of celiac disease and gluten intolerance, announced today the introduction of its Bone Health supplement. The product launch comes after the recent introduction of Celi•Vites Blood Health and Body Health products, both released late last year.

According to Leigh Reynolds, company principal and president, the Bone Health formulation rounds out the product line by addressing one of the most dramatic concerns facing those with celiac disease or gluten intolerance: thinning bones or osteoporosis and osteopenia.

"Bone health is one of the biggest concerns for celiac sufferers, because loss of bone density is a dangerous condition that can affect the quality of life," explained Reynolds. "This product is specially formulated to help restore bone health and complements the nutritional components found in our other two products. Together, the three products create a nutritional powerhouse."

Celi•Vites bone health is made with three key ingredients: vitamin K2, a rarer form of vitamin K than what is found in most vitamins; calcium citrate, a form of calcium that is much easier to absorb that the calcium carbonate found in most vitamins; and aquamin, a calcium source that has been found to be an effective bone builder in a mouse model of osteoporosis. Because 98 percent of adults do not get the recommended daily values of potassium, Celi•Vites Bone Health also contains potassium citrate. Finally it contains 1,000 IU of vitamin D.

Dr. Taylor Reynolds, vice president of research and development at Gluten Free Therapeutics and a celiac patient herself, explains how Celi•Vites are formulated to make a real difference to celiac sufferers.

"Bone Health by Celi•Vites is unique among bone health supplements, because it contains balanced proportions of calcium, magnesium and potassium citrate as well as 180mcg of Vitamin K2 as menaquinone-7 (MK-7)," explained Dr. Reynolds. "In a clinical study, postmenopausal women taking 180mcg of MK-7 over a three-year period had decreased bone loss*; we felt that research was compelling enough to include MK-7 in our product.

"When building bone, you have the have the right ratio of calcium to magnesium," Dr. Reynolds continued. "We worked with formulators for more than a year to get this absolutely right, formulating Celi•Vites Bone Health to not only meet strict gluten-free specifications, but also to ensure that it is the absolute best product in its class. We believe celiac sufferers will find it an important addition to their health regimens."

Bone Health by Celi•Vites specifications:

  •     180mcg of Vitamin K2 as menaquinone-7 (MK-7)
  •     500mg of calcium; 50% as calcium citrate and 50% as Aquamin®, a highly absorbable source of calcium derived from Litothamnion coralliodes, a red algae from the Atlantic waters off the coast of Ireland and Iceland. As a marine plant-derived extract, in addition to calcium, Aquamin® contains magnesium and over 70 trace and ultra-trace minerals
  •     Balanced proportions of magnesium (250mg) and potassium (1000mg) citrate
  •     1000 IU of Vitamin D3
  •     Delightful orange flavor – simply add powder to juice or water

*Knapen M.H.J., et al. (2013) Three-year low-dose meanquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 9:2499-507. PMID:23525894

About Leigh and Taylor Reynolds
With more than two decades of experience as executive management in the pharmaceutical and retail sectors, before launching Celi•Vites, Leigh Reynolds was the chief operating officer of a Boston-based pharmaceutical company with multinational distribution and was responsible for the company’s highly successful startup through its profitable sale. Her expertise includes supply chain sourcing and management, quality and regulatory system oversight, product development, manufacturing, marketing, and sales.

Leigh's daughter, Dr. Taylor Reynolds, is a veterinary pathologist/scientist with a focus on the immune system. She received her B.A. from Colorado College, D.V.M. from Tufts University School of Veterinary Medicine, and Ph.D. from Johns Hopkins University School of Medicine. While studying for her residency in her early 30s, Taylor was diagnosed with celiac disease and her symptoms, as for many celiacs, were challenging: she suffered extreme fatigue, weight loss, thinning hair, profound anemia and osteopenia. Finally diagnosed, her symptoms abated when she removed gluten from her diet, but her nutritional testing remained subpar. Today, in addition to her thriving career, she serves as the vice president of research and development at Gluten Free Therapeutics.

About Gluten Free Therapeutics/Celi•Vites
Maine-based Gluten Free Therapeutics is the parent company of Celi•Vites, a line of scientifically formulated nutritional supplements designed specifically for those suffering from the debilitating effects of celiac disease or gluten intolerance. Company founders are committed to creating the highest quality products on the market, and therefore, Celi•Vites are made with the most innovative, efficacious and safe gluten-free ingredients available. The company formulated the line by mining data from in-depth medical research, partnering with industry leaders and implementing contemporary best practices. The Body Health, Blood Health and Bone Health supplements are available online at The line has been spotlighted by high-profile gluten-free lifestyle outlets, including Living Without magazine, Gluten Free Living magazine, Celiac Chicks, Celiac Corner, and Gluten Free Gigi as well as trade and medical publications such as Vitamin Retailer and Practical Gastroenterology.


For more information on Celi•Vites or to schedule an interview with Leigh or Taylor Reynolds, contact Ann Ewing, Ewing Communications, at 615-419-3753 or

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ann ewing